Goldman Sachs Highlights Corvus Pharmaceuticals as a Promising Oral Player in $24 Billion Atopic Dermatitis Market

Goldman sees Corvus as a buy: its oral eczema drug could rival Dupixent and grow into multiple diseases, boosting the stock potential.